Prozac to Withdraw from Taiwan in April

| By | Chinese Pharma, Eli Lilly

The popular antidepressant Prozac is to be permanently removed from pharmacy shelves this April in Taiwan, announced the drug’s Taiwanese manufacturer Zuellig Pharma (裕利藥廠) last week, reported CNA.

Claiming to be unable to cope with frequent price cuts by Taiwan’s National Health Insurance (NHI), the local Taiwanese maker of the Prozac 20 mg, Zuellig Pharma, announced last week that it will stop selling the antidepressant in Taiwan on April 1. The company said that it will completely withdraw the drug from the Taiwan market, but all orders received before March 29 will still be fully supplied.

On March 13, the company sent a letter to all hospitals announcing that due to the annual reduction of drug prices by the National Health Insurance Administration, along with an increase in raw material and transportation costs in recent years, it will be ceasing the supply of Prozac. The company also mentioned the rising costs of following the Pharmaceutical Inspection Co-operation Scheme (PICS) and Good Manufacturing Practice (GMP) to ensure the quality of the medication.

Zuellig Pharma said that after taking the above-mentioned factors into an actuarial analysis, it was notified by Eli Lily Taiwan, the owner of Prozac, to cease production on April 1 and withdraw the product from the Taiwan market. In order to ensure the rights of hospitals and patients, the company said that orders received before March 29 will be fully supplied.

In an interview with CNA, Chang Wen-ching, spokesman for the Taiwan Pharmacist Association, said Prozac is a commonly used drug in treating depression. Chang said that it is a widely used first-line drug because of its long history of use and relatively fewer side effects.

For these reasons, its usage rate is very high, and in recent years, the cost of this drug under NHI coverage per tablet has dropped from NT$2.08 (US$0.067) to NT$1.96 (US$0.063).

SOURCE: Taiwan News
GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.